Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Abbott Laboratories Market Cap
From what 27 stock analysts predict, the share price for Abbott Laboratories (ABT) might increase by 12.44% in the next year. This is based on a 12-month average estimation for ABT. Price targets go from $104 to $149. The majority of stock analysts believe ABT is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 27 Wall Street analysts have assigned ABT 21 buy ratings, 5 hold ratings, and 1 sell ratings. This means that analysts expect Abbott Laboratories to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ABT. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ABT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Matt Miksic Barclays | Overweight | $149 | Maintains | Nov 5, 2024 |
| Adam Maeder Piper Sandler | Overweight | $133 | Maintains | Oct 17, 2024 |
| Anthony Petrone Mizuho | Neutral | $130 | Maintains | Oct 17, 2024 |
| Lee Hambright Bernstein | Outperform | $138 | Maintains | Oct 17, 2024 |
| David Lewis Morgan Stanley | Equal-Weight | $117 | Maintains | Oct 17, 2024 |
| Matthew Taylor Jefferies | Hold | $125 | Maintains | Oct 17, 2024 |
| Danielle Antalffy UBS | Buy | $146 | Maintains | Oct 17, 2024 |
| Jayson Bedford Raymond James | Outperform | $129 | Maintains | Oct 14, 2024 |
| Suraj Kalia Oppenheimer | Outperform | $130 | Initiates | Oct 8, 2024 |
| Shagun Singh RBC Capital | Outperform | $130 | Maintains | Oct 8, 2024 |
| Vijay Kumar Evercore ISI Group | Outperform | $124 | Maintains | Oct 1, 2024 |
| Raj Denhoy Jefferies | Hold | $120 | Reiterates | Sep 26, 2024 |
| Adam Maeder Piper Sandler | Overweight | $131 | Initiates | Sep 19, 2024 |
Jefferies | Buy | Maintains | Aug 27, 2024 | |
| Joanna Wiensch Citigroup | Buy | $127 | Maintains | Aug 22, 2024 |
| Matt Miksic Barclays | Overweight | $143 | Maintains | Jul 29, 2024 |
| Vijay Kumar Evercore ISI Group | Outperform | $120 | Maintains | Jul 2, 2024 |
| Shagun Singh RBC Capital | Outperform | $125 | Reiterates | Jun 4, 2024 |
| David Roman Goldman Sachs | Buy | $121 | Initiates | May 30, 2024 |
| Joanna Wiensch Citigroup | Buy | $119 | Maintains | May 22, 2024 |
When did it IPO
1983
Staff Count
114,000
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Robert B. Ford
Market Cap
$199.29B
In 2023, ABT generated $40.11B in revenue, which was a decrease of -8.12% from the previous year. This can be seen as a signal that ABT's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Sat, 07 Dec 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Nearly 20,000 participants donated blood in the Abbott-Big Ten competition, potentially saving 60,000 lives. Nebraska won and received $1M from Abbott for health initiatives.
Why It Matters - The Abbott-Big Ten blood donation initiative enhances Abbott's brand visibility and community engagement, potentially boosting its stock performance and investor confidence in corporate social responsibility.
Wed, 04 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Abbott (ABT) is currently attracting attention from Zacks.com users, indicating potential interest and factors influencing the stock's future performance.
Why It Matters - Increased attention from Zacks.com users may indicate heightened interest or volatility in Abbott's stock, potentially influencing its price movements and investment decisions.
Thu, 05 Dec 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Analyst recommendations from brokerage firms influence stock prices, prompting investors to consider these ratings when deciding to buy, sell, or hold stocks.
Why It Matters - Analyst recommendations can significantly sway stock prices, impacting investor sentiment and trading decisions, which in turn affects market volatility and potential returns.
Thu, 05 Dec 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Abbott (ABT) closed at $115.59, down 0.33% from the previous trading session.
Why It Matters - Abbott's slight decline indicates potential volatility, signaling a need for investors to monitor market sentiment and performance trends closely.
Fri, 29 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Abbott is positioned to expand a capital-efficient licensing model, potentially increasing access to essential medicines for emerging market populations.
Why It Matters - Abbott's capital-efficient licensing model can expand market reach and revenue potential in emerging markets, enhancing its growth prospects and long-term shareholder value.
Fri, 29 Nov 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Abbott (ABT) closed at $118.77, reflecting a decrease of 0.15% from the previous trading day.
Why It Matters - Abbott's slight decline in stock price reflects market sentiment and potential concerns, influencing investor perceptions and future trading strategies.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
